Choosing The Best mRNA Manufacturing Strategy: In-House, Outsourcing, Or Blended

mRNA-based therapeutics are reshaping the biopharma landscape, but success depends on more than scientific innovation; it requires the right manufacturing strategy. Should you build in-house capabilities, outsource to a CDMO, or combine both? Each approach offers distinct advantages and challenges. In-house manufacturing provides control over quality, timelines, and IP, but demands significant investment and expertise. Outsourcing offers speed, flexibility, and access to specialized technologies, yet introduces risks around IP and responsiveness. A blended model can deliver the best of both worlds, balancing control with scalability. Explore key considerations—technology, cost, and flexibility—to determine the optimal path for your organization’s mRNA manufacturing journey.

Read the full article to uncover strategic insights for future-ready operations.